The recent cagrisema results suggest that Novo Nordisk’s next weight-loss drug is unlikely to differ significantly from Eli Lilly’s Zepbound, according to Bloomberg Intelligence.
发布者:BY MARKETWIRE,转转请注明出处:https://robotalks.cn/novos-disappointing-cagrisema-data-could-give-eli-lilly-the-upper-hand/